Another study confirmed the secretory nature of mutant p53, revealing that secreted mutant p53 can inhibit glycolysis, leading to the reduction in and dysfunction of CD4+ T lymphocytes, thus altering the tumor immune microenvironment [68]. The gene discussed is TP53; the disease is neoplasm.